A review of the use of adapalene for the treatment of acne vulgaris

Suleyman Piskin, Erol Uzunali, Suleyman Piskin, Erol Uzunali

Abstract

Acne is a disease of the pilosebaceous unit with involving abnormalities in sebum production, microbial flora changes, abnormal keratinization, and inflammation. There are several therapeutic options like topical and systemic retinoids, antibiotics, and systemic hormonal drugs. The topical retinoids a play very important role in the treatment of acne vulgaris. However, their use is limited due to skin irritation. A new generation product, adapalene is a good choice in the treatment of acne vulgaris with less side effects and high efficacy confirmed by numerous clinical studies.

Keywords: acne vulgaris; adapalene; treatment.

Figures

Figure 1
Figure 1
Structural formula of adapalene.

References

    1. Bergfeld WF. The evolving role of retinoids in the management of cutaneous conditions. Clinician. 1998;16:1–32.
    1. Bershad S, Kranjac Singer GK, Parente JE, et al. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol. 2002;138:481–9.
    1. Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparision of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol. 2003;49:S227–32.
    1. Braun-Falco O, Plewig G, Wolff HH, et al. Dermatology. 2. Berlin: Springer-Verlag; 2001.
    1. Cunliffe WJ, Caputo R, Dreno B, et al. Clinical efficacy and safety comparision of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol. 1997;36:S126–34.
    1. Cunliffe WJ, Holland DB, Clark SM, et al. Comedogenesis: some aetiological, clinical and theurapeutic strategies. Dermatology. 2003;206:11–6.
    1. Cunliffe WJ, Poncet M, Loesche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998;139(Suppl 52):48–56.
    1. Cunliffe WJ, Simpson NB. Disorders of sebaceous glands. In: Champion RH, Burton JL, Burns DA, Brethnach SM, editors. Rook/Wilkinson/Ebling Textbook of dermatology. 6. Milan: Blackwell Science Ltd; 1998. pp. 1927–84.
    1. Czernielewski J, Michel S, Bouclier M, et al. Adapalene biochemistry and the evaluation of a new topical retinoid for treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(Suppl 3):5–12.
    1. do Nascimento LV, Guedes ACM, Magalhães GM, et al. Single-blind comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% gel (QD) in the treatment of acne vulgaris for 11 weeks. J Dermatol Treat. 2003;14:166–71.
    1. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1% Cutis. 2005;75:289–93.
    1. Ellis CN, Millikan LE, Smith EB, et al. Comparision of adalapene 0.1% solution and tretinoin 0.025% gel in topical treatment of acne vulgaris. Br J Dermatol. 1998;139(Suppl 52):41–7.
    1. Grosshans E, Marks R, Mascaro JM, et al. Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol. 1998;139(Suppl 52):26–33.
    1. Guenther LC. Optimizing treatment with topical tazarotene. Am J Clin Dermatol. 2003;4:197–202.
    1. Habif TP, Habie TP. Clinical dermatology: A color guide to diagnosis and therapy. Philadelphia: Mosby Co; 1996.
    1. Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical study. Br J Dermatol. 2002;147:523–27.
    1. James WD, Berger TG, Elston DM. Acne. Andrews’ diseases of the skin Clinical Dermatology. 10. Philadelphia: WB Saunders Company; 2000.
    1. Kligman AM. The growing importance of topical retinoids in clinical dermatology: a retrospective and prospective analysis. J Am Acad Dermatol. 1998;39:S2–7.
    1. Korkut C, Piskin S. Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. J Dermatol. 2005;32:169–73.
    1. Leyden JJ. New understandings of the pathogenesis of acne. J Am Acad Dermatol. 1995;32:S15–25.
    1. Leyden JJ. Topical treatment of acne vulgaris: retinoids and cutaneous irritation. J Am Acad Dermatol. 1998;38:S1–4.
    1. Millikan LE. Adapalene: an update on newer comparative studies between the various retinoids. Int J Dermatol. 2000;39:784–8.
    1. Nyirady J, Grossman RM, Nighland M, et al. A comparative trial of two retinoids commonly used in the treatment of acne vulgaris. J Dermatol Treat. 2001;12:149–57.
    1. Oberemok SS, Shalita AR. Acne vulgaris, II: treatment. Cutis. 2002;70:111–4.
    1. Pariser DM, Thiboutot DM, Clark SD, et al. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: A randomized, multicenter, investigator-blinded, controlled comparision study versus adapalene gel 0.1% and vehicle. Cutis. 2005;76:145–51.
    1. Skov MJ, Quigley JW, Bucks DA. Topical delivery system for tretinoin: research and clinical implications. J Pharm Sci. 1997;86:1138–43.
    1. Strasburger VC. Acne. What every pediatrician should know about treatment? Pediatr Clin North Am. 1997;44:1505–23.
    1. Strauss JS, Thiboutot DM. Diseases of sebaceous glands. In: Freedberg MI, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, editors. Dermatology in general medicine. 5. New York: McGraw Hill Co; 1999. pp. 769–84.
    1. Thiboutot D, Gold MH, Jarratt MT, et al. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis. 2001;68(4 Suppl):10–9.
    1. Thiboutot D, Pariser DM, Egan N, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol. 2006a;54:242–50.
    1. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris; a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol. 2006b;142:597–602.
    1. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed. 2005;4:138–46.
    1. Zhang JZ, Li LF, Tu YT, et al. A successful maintenance approach in inflammatory acne with adapalane gel 0.1% after an initial treatment in combination with clindamycin topical solution 1% or after monotherapy with clindamycin topical solution 1% J Dermatol Treat. 2004;15:372–8.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj